Literature DB >> 4736995

Physical properties and antigenic components of Oriboca virus.

N Karabatsos.   

Abstract

Two complement fixation (CF) components were detected in all of the various preparations (mouse liver, brain, serum, and BHK-21 cell culture) of Oriboca examined by equilibrium density centrifugation. The CF components possessed a buoyant density of 1.21 and 1.18 g/ml, and they were precipitated by treatment with protamine. Analysis of Oriboca virus by rate zonal sedimentation separated three components. The most rapidly sedimenting component was the infectivity which cosedimented with a peak of hemagglutinating (HA) activity designated VHA. A second, more slowly sedimenting, noninfectious HA component (HA-2) was followed by a peak of CF activity which barely moved from the top of the gradient. The single rate zonal CF peak and the two density gradient CF components were broadly cross-reactive serologically with Murutucu antiserum. They could not be identified as Oriboca on the basis of their CF reactions with Murutucu and Oriboca antisera. Oriboca-infective virions possessed an equilibrium density of 1.20 g/ml if derived from BHK-21 cell culture fluid concentrates or mouse serum. Infective virions prepared from mouse brain or liver banded at a buoyant density of 1.17 to 1.18 g/ml. These density differences, along with observed differences in reactivity with protamine and in rate of neutralization, are consistent with the interpretation that these are related to the problem of whether the source preparations of Oriboca represented primarily intracellular or extracellular particles.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4736995      PMCID: PMC422809          DOI: 10.1128/iai.8.1.53-62.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  STUDIES ON THE BAI STRAIN A (AVIAN MYELOBLASTOSIS) VIRUS. I. PRODUCTION AND EXAMINATION OF POTENT VIRUS-SPECIFIC COMPLEMENT-FIXING ANTISERA.

Authors:  E A ECKERT; R ROTT; W SCHAEFER
Journal:  Virology       Date:  1964-11       Impact factor: 3.616

2.  EXTRACTION OF CELL-ASSOCIATED VIRUS WITHOUT DAMAGE OF THE CULTURE. (BRIEF REPORT).

Authors:  C HALLAUER; G KRONAUER
Journal:  Arch Gesamte Virusforsch       Date:  1965

3.  Further studies on the serological relationships of group C arthropod-borne viruses and the application of these relationships to rapid identification of types.

Authors:  R E SHOPE; O R CAUSEY
Journal:  Am J Trop Med Hyg       Date:  1962-03       Impact factor: 2.345

4.  Group C, a new serological group of hitherto undescribed arthropod-borne viruses. Immunological studies.

Authors:  J CASALS; L WHITMAN
Journal:  Am J Trop Med Hyg       Date:  1961-03       Impact factor: 2.345

5.  Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses.

Authors:  D H CLARKE; J CASALS
Journal:  Am J Trop Med Hyg       Date:  1958-09       Impact factor: 2.345

6.  Cross-neutralization studies with group C arboviruses.

Authors:  N Karabatsos; J R Henderson
Journal:  Acta Virol       Date:  1969-11       Impact factor: 1.162

7.  Characterization of viruses isolated from bats.

Authors:  N Karabatsos
Journal:  Am J Trop Med Hyg       Date:  1969-09       Impact factor: 2.345

8.  Susceptibility of the baby-hamster kidney-cell line (BHK-21) to infection with arboviruses.

Authors:  N Karabatsos; S M Buckley
Journal:  Am J Trop Med Hyg       Date:  1967-01       Impact factor: 2.345

9.  Electron microscopic observations of mouse brain infected with Bunyamwera group arboviruses.

Authors:  F A Murphy; A K Harrison; T Tzianabos
Journal:  J Virol       Date:  1968-11       Impact factor: 5.103

10.  Dengue virions and antigens in brain and serum of infected mice.

Authors:  W E Brandt; R D Cardiff; P K Russell
Journal:  J Virol       Date:  1970-10       Impact factor: 5.103

View more
  1 in total

1.  Structural components of Oriboca virus.

Authors:  R R Rosato; M L Robbins; G A Eddy
Journal:  J Virol       Date:  1974-04       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.